Home > Journals > Minerva Pediatrics > Past Issues > Minerva Pediatrica 2018 October;70(5) > Minerva Pediatrica 2018 October;70(5):418-24



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Pediatrica 2018 October;70(5):418-24

DOI: 10.23736/S0026-4946.18.05203-9


language: English

Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB12 and Enterococcus faecium L3 in atopic children

Francesco DI PIERRO 1 , Isabella BASILE 2, Maria L. DANZA 3, Leo VENTURELLI 4, Raffaele CONTINI 5, Paolo RISSO 6, Maria COLOMBO 5

1 Scientific and Research Department, Velleja Research, Milan, Italy; 2 ASL District 6, Cologno Monzese, Milan, Italy; 3 ASL District 6, Binasco, Milan, Italy; 4 ATS Bergamo, Bergamo, Italy; 5 ATS Milano, Vignate, Milan, Italy; 6 Department of Health Sciences, University of Genoa, Genoa, Italy

BACKGROUND: Imbalance of the human gut microbiota in childhood, mainly due to low gut biodiversity and a low bifidobacterial load, has been suggested as a risk factor for atopy. Administration of Enterococcus faecium L3 in infants has been shown to increase the gut bifidobacterial count. The aim was to verify if a mixture of Bifidobacterium animalis subsp. lactis BB12 and E. faecium L3 could reduce the signs, symptoms and need for drugs in atopic children.
METHODS: We retrospectively analyzed, and compared with controls, clinical outcomes following use of BB12 and L3 strains when administered 3 months before or during the development of signs and symptoms of atopy.
RESULTS: When administered in the 3 months before the development of atopy, the BB12 and L3 strains significantly reduced (P<0.001) rhinitis, watery eyes and cough/bronchospasm. However, reduced efficacy was observed when the mixture was given during the 3 months of atopy. The mixture of strains also significantly reduced the use of oral antihistamines, inhaled corticosteroids (in the same children in two different years) and oral corticosteroids (in different children in the same year).
CONCLUSIONS: When administered as a prophylactic, the mixture of BB12 and L3 (iNatal Ped®) statistically decreases the signs and symptoms of atopy and reduces the use of drugs. Administration of the same probiotics as treatment after the appearance of atopy is less effective.

KEY WORDS: Hypersensitivity - Asthma - Rhinitis - Lacrimal apparatus diseases - Cough - Bronchial spasm

top of page